Analysts think FBRX stock price could increase by 465%
Aug 01, 2024, 6:26 AM
0.00%
What does FBRX do
Forte Biosciences, Inc., a Dallas-based biopharmaceutical company with nine employees, specializes in dermatology products and services and went public on April 13, 2017. The company is developing FB-102, a therapeutic molecule aimed at treating autoimmune conditions like GvHD, vitiligo, and alopecia areata.
5 analysts think FBRX stock price will increase by 464.58%. The current median analyst target is $3.06 compared to a current stock price of $0.54. The lowest analysts target is $2.78 and the highest analyst target is $4.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
